Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Biol Chem ; 292(22): 9034-9050, 2017 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-28373279

RESUMO

The accumulation of α-synuclein (α-syn) fibrils in neuronal inclusions is the defining pathological process in Parkinson's disease (PD). A pathogenic role for α-syn fibril accumulation is supported by the identification of dominantly inherited α-syn (SNCA) gene mutations in rare cases of familial PD. Fibril formation involves a spontaneous nucleation event in which soluble α-syn monomers associate to form seeds, followed by fibril growth during which monomeric α-syn molecules sequentially associate with existing seeds. To better investigate this process, we developed sensitive assays that use the fluorescein arsenical dye FlAsH (fluorescein arsenical hairpin binder) to detect soluble oligomers and mature fibrils formed from recombinant α-syn protein containing an N-terminal bicysteine tag (C2-α-syn). Using seed growth by monomer association (SeGMA) assays to measure fibril growth over 3 h in the presence of C2-α-syn monomer, we observed that some familial PD-associated α-syn mutations (i.e. H50Q and A53T) greatly increased growth rates, whereas others (E46K, A30P, and G51D) decreased growth rates. Experiments with wild-type seeds extended by mutant monomer and vice versa revealed that single-amino acid differences between seed and monomer proteins consistently decreased growth rates. These results demonstrate that α-syn monomer association during fibril growth is a highly ordered process that can be disrupted by misalignment of individual amino acids and that only a subset of familial-PD mutations causes fibril accumulation through increased fibril growth rates. The SeGMA assays reported herein can be utilized to further elucidate structural requirements of α-syn fibril growth and to identify growth inhibitors as a potential therapeutic approach in PD.


Assuntos
Amiloide/química , Mutação de Sentido Incorreto , Doença de Parkinson , Agregação Patológica de Proteínas , alfa-Sinucleína/química , Substituição de Aminoácidos , Amiloide/genética , Amiloide/metabolismo , Humanos , alfa-Sinucleína/genética , alfa-Sinucleína/metabolismo
2.
Clin Geriatr Med ; 37(2): 289-300, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33858611

RESUMO

Patients with cancer may experience neuropathy at any stage of malignancy, ranging from symptoms that are the earliest signs of cancer to side effects of treatment. Peripheral nerves are affected most commonly in a symmetric, stocking-glove pattern. Sensory neuronopathies, plexopathies, and radiculopathies may also be seen. The most common type of neuropathy in patients with cancer is related to chemotherapy, and recently peripheral nerve complications have been described as an effect of immune checkpoint inhibitors too. Other causes include paraneoplastic syndromes, direct tumor infiltration, and radiation. Treatment focuses on addressing the underlying cancer and management of neuropathic pain.


Assuntos
Neuropatias do Plexo Braquial/etiologia , Neoplasias/complicações , Síndromes Paraneoplásicas , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Lesões por Radiação/complicações , Antineoplásicos/efeitos adversos , Neuropatias do Plexo Braquial/diagnóstico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Neoplasias/tratamento farmacológico , Síndromes Paraneoplásicas/induzido quimicamente , Síndromes Paraneoplásicas/diagnóstico , Doenças do Sistema Nervoso Periférico/complicações , Lesões por Radiação/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA